Clinical trials: Langerhans Cell Histiocytosis (LCH), open to volunteers
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back…
- Trial name
- NCT05828069
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 123 sites in United States, Australia and 1 more
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06712810
- Testing
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Mayo Clinic
Langerhans Cell Histiocytosis
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric…
- Trial name
- NCT06582745
- Testing
- Trametinib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Cook Children's Health Care System
Adrenal Gland Pheochromocytoma, Carcinoma In Situ
Project: Every Child for Younger Patients With Cancer
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and…
- Conditions
- Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma
- Trial name
- NCT02402244
- Testing
- Cytology Specimen Collection Procedure, Medical Chart Review
- Where
- 279 sites in United States, Australia and 4 more
- Volunteers
- 75,000 people
- Sponsor
- Children's Oncology Group
Histiocytosis, Histiocytosis, Langerhans-Cell
Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
The long-term outcomes of adult patients with pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, is largely unknown.
- Conditions
- Histiocytosis, Histiocytosis, Langerhans-Cell, Histiocytosis Pulmonary
- Trial name
- NCT04665674
- Testing
- Standard of care
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Langerhans Cell Histiocytosis of Bone
Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
Langerhans cell histiocytosis (LCH) of bone is a benign-tumor-like osteolytic lesion in childhood and adolescence, which is characterized by the aberrant activation of antigen presenting cells.
- Trial name
- NCT06078969
- Testing
- Prednisone
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Shanghai Changzheng Hospital
Langerhans Cell Histiocytosis (LCH)
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder in children, caused by excessive proliferation and accumulation of Langerhans cells (a type of immune cell) in various body tissues.
- Trial name
- NCT07431060
- Testing
- Prednisone, Vincristine, Mercaptopurine
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- West China Second University Hospital
Histiocytosis,Langerhans-Cell
A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents
Based on clinical observation data from two previously enrolled cases, the adezbelimab combined with trametinib regimen showed good safety in pediatric refractory relapsed LCH, with good drug tolerance.
- Trial name
- NCT07890701
- Testing
- treated group
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Langerhans Cell Histiocytosis, LCH
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
This is a rare disease, single-arm, open-label,multi-center, non-randomized Phase 2 clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of FCN-159 monotherapy in pediatric patients with…
- Trial name
- NCT05997602
- Testing
- FCN-159
- Where
- 11 sites in China
- Volunteers
- 56 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Langerhans Cell Histiocytosis
Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis
This single-center, prospective, interventional phase 2 study evaluates a response-adapted treatment strategy for patients aged 10 years and older with histologically confirmed Langerhans cell histiocytosis requiring systemic…
- Trial name
- LUCAS (NCT07728201)
- Testing
- Luvometinib, Luvometinib, Cytarabine.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Langerhans Cell Histiocytosis
Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
Treatment of Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis (LCH) Using a Low-Dose Cytarabine Combined with Thalidomide Regimen.
- Trial name
- NCT07187193
- Testing
- Cytarabine (Ara-C), Thalidomide (100mg)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Histiocytosis, Langerhans-Cell
Biomarkers for Diagnostic, Prognostic and of Response to Treatment in Adult Langerhans Cell Histiocytosis
Adult Langerhans histiocytosis (LCH) is a rare disease of unknown etiology, characterized by the activation of the MAPK (Mitogen-activated protein kinases) pathway, driven by various somatic mutations in the specific lesions of…
- Trial name
- BIOHISTIO (NCT06197204)
- Testing
- Blood sampling, Biopsy
- Where
- France
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG)
Mirdametinib in Histiocytic Disorders
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
- Conditions
- Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders
- Trial name
- NCT06153173
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Erdheim-Chester Disease
Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
The investigators want to understand more about what kinds of health problems are caused by histiocytosis, what happens as a result of different treatments, and how ECD affects people's lives, their feelings and their attitudes.
- Trial name
- NCT03329274
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Histiocytosis, Langerhans Cell Histiocytosis
Histiocytic Disorder Follow-up Study
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific…
- Conditions
- Histiocytosis, Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai Dorfman Disease
- Trial name
- NCT05915208
- Where
- United States
- Volunteers
- 6,000 people
- Sponsor
- University of Alabama at Birmingham
Langerhans Cell Histiocytosis (LCH)
Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children
Langerhans cell histiocytosis (LCH) is the most common histiocytosis in children, with an incidence of 2.6-8.9 per million. It is an inflammatory myeloid tumor with varied symptoms.
- Trial name
- NCT07022834
- Testing
- Dabrafenib or Trametinib and Clofarabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Second University Hospital
Langerhans Cell Histiocytosis
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Langerhans Cell Histiocytosis (LCH) is a type of cancer that can damage tissue or cause lesions to form in one or more places in the body.
- Trial name
- NCT02670707
- Testing
- Cytarabine, Vinblastine/prednisone
- Where
- 11 sites in United States
- Volunteers
- 124 people
- Sponsor
- Baylor College of Medicine
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment.
- Conditions
- Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease
- Trial name
- NACHO-COBI (NCT04079179)
- Testing
- Cobimetinib
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- Carl Allen
Langerhans Cell Histiocytosis (LCH)
Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
Langerhans cell histiocytosis (LCH) is the most common type of histiocytic disorder in children, affecting about 2.6 to 8.9 out of every million kids each year.
- Trial name
- NCT07371182
- Testing
- Luvometinib
- Where
- 11 sites in China
- Volunteers
- 62 people
- Sponsor
- West China Second University Hospital